Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
Osteoarthritis

About this trial
This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, chronic pain, opioid, transdermal
Eligibility Criteria
Inclusion Criteria: documented history and/or radiologic evidence of chronic osteoarthritis of the hip or knee. receiving opioid therapy for osteoarthritis-related pain within the past year or have experienced pain that was inadequately controlled with a full standard dose of NSAIDs. Exclusion Criteria: receiving opioids at an average daily dose of greater than 90 mg of oral morphine equivalents or patients receiving more than 12 tablets or capsules per day of short-acting opioid-containing products scheduled to have surgery (including dental) during the study period that involved the use of pre- and/or postoperative analgesics or anesthetics. Other protocol-specific exclusion/inclusion criteria may apply.
Sites / Locations
- Hawthorne & York, International, Ltd.
- Arizona Research Center, LLC
- ACRC/Arizona Clinical Research
- Advanced Clinical Therapeutics
- San Diego Arthritis and Osteoporosis Research
- Scripps Clinic Rancho Bernardo
- Clinical Research Consultants, Inc.
- Tampa Bay Medical Research, Inc.
- University Clinical Research
- Gainesville Clinical Research Center
- Physicians Research Associates Jacksonville
- University Clinical Research, Inc.
- Gold Coast Research, Inc.
- MediSphere Medical Research Center, LLC
- Westside Family Medical Center
- Center for Pharmaceutical Research
- NJP Clinical Research
- PW Clinical Research, LLC
- New Century Research Center, Ltd.
- Altoona Center for Clinical Research
- Mid-South Clinical Research Institute
- Advanced Clinical Research